Also trades as: 0UNL.L (LSE) · $vol 0M
NKTR Smart Money
Nektar Therapeutics
1W: -3.2%
1M: -37.1%
3M: -46.3%
YTD: -12.6%
1Y: -36.8%
3Y: +390.6%
5Y: -84.8%
$37.97
+0.52 (+1.39%)
Weekly Expected Move ±13.7%
$27
$32
$37
$42
$47
Credit Risk of going bust: higher than 66% of companies Debt: 11.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026287
Institutions Holding
+49 vs prior
231.4%
Ownership
+53.71%
78
New
100
Increased
84
Reduced
43
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | GREER R SCOTT | director | A-Grant/Award | 2,000 | $— | $0 | Filing |
| 2026-09-23 | CHESS ROBERT | director | A-Grant/Award | 2,000 | $— | $0 | Filing |
| 2026-09-23 | WHITFIELD ROY A | director | A-Grant/Award | 2,000 | $— | $0 | Filing |
| 2026-09-23 | Ajer Jeffrey Robert | director | A-Grant/Award | 2,000 | $— | $0 | Filing |
| 2026-09-23 | Brainard Diana | director | A-Grant/Award | 2,000 | $— | $0 | Filing |
| 2026-08-18 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 418 | $71.98 | $30K | Filing |
| 2026-08-18 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 186 | $71.98 | $13K | Filing |
| 2026-06-30 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 5,681 | $70.00 | $398K | Filing |
| 2026-06-17 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 4,500 | $61.65 | $277K | Filing |
| 2026-06-17 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 5,500 | $60.81 | $334K | Filing |
| 2026-06-16 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 4,697 | $60.71 | $285K | Filing |
| 2026-06-16 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 5,303 | $59.97 | $318K | Filing |
| 2026-06-15 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 5,538 | $60.71 | $336K | Filing |
| 2026-05-19 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 444 | $65.51 | $29K | Filing |
| 2026-05-19 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 199 | $65.51 | $13K | Filing |
| 2026-02-18 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 180 | $73.00 | $13K | Filing |
| 2026-02-18 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 423 | $73.00 | $31K | Filing |
| 2026-01-20 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 3,867 | $35.67 | $138K | Filing |
| 2025-12-22 | Zalevsky Jonathan | officer: chief r&d officer | A-Grant/Award | 6,250 | $— | $0 | Filing |
| 2025-12-22 | ROBIN HOWARD W | officer: president & ceo | A-Grant/Award | 21,667 | $— | $0 | Filing |
| 2025-11-25 | Wilson Mark Andrew | officer: chief legal officer | S-Sale | 630 | $54.28 | $34K | Filing |
| 2025-11-25 | Zalevsky Jonathan | officer: chief r&d officer | S-Sale | 1,157 | $54.28 | $63K | Filing |
| 2025-11-25 | ROBIN HOWARD W | officer: president & ceo | S-Sale | 2,207 | $54.28 | $120K | Filing |
| 2025-11-21 | Zalevsky Jonathan | officer: chief r&d officer | A-Grant/Award | 2,666 | $— | $0 | Filing |
| 2025-11-21 | Wilson Mark Andrew | officer: chief legal officer | A-Grant/Award | 1,903 | $— | $0 | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| FMR LLC | 5,067,920 | $354M | +764,732 | 2026-06-30 | Filing |
| Two Seas Capital LP | 3,092,234 | $216M | +1,133,056 | 2026-06-30 | Filing |
| BlackRock, Inc. | 2,941,851 | $205M | +2,249,201 | 2026-06-30 | Filing |
| BVF INC/IL | 2,391,075 | $167M | -168,520 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,496,849 | $104M | +299,794 | 2026-06-30 | Filing |
| TWO SIGMA INVESTMENTS, LP | 1,202,004 | $84M | +271,263 | 2026-06-30 | Filing |
| Vestal Point Capital, LP | 1,000,000 | $70M | +715,000 | 2026-06-30 | Filing |
| MORGAN STANLEY | 936,560 | $65M | +277,173 | 2026-06-30 | Filing |
| STATE STREET CORP | 909,679 | $64M | +664,952 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 881,306 | $62M | +534,511 | 2026-06-30 | Filing |
| Prosight Management, LP | 810,000 | $57M | +75,000 | 2026-06-30 | Filing |
| ARMISTICE CAPITAL, LLC | 724,000 | $51M | +146,000 | 2026-06-30 | Filing |
| GILDER GAGNON HOWE & CO LLC | 600,873 | $42M | +329,115 | 2026-06-30 | Filing |
| MILLENNIUM MANAGEMENT LLC | 478,120 | $33M | +73,843 | 2026-06-30 | Filing |
| BRAIDWELL LP | 473,617 | $33M | +250,916 | 2026-06-30 | Filing |
| Sofinnova Investments, Inc. | 471,763 | $33M | -37,783 | 2026-06-30 | Filing |
| Woodline Partners LP | 470,875 | $33M | +55,540 | 2026-06-30 | Filing |
| ORBIMED ADVISORS LLC | 465,346 | $32M | +190,346 | 2026-06-30 | Filing |
| UBS Group AG | 428,400 | $30M | +108,228 | 2026-06-30 | Filing |
| EMERALD ADVISERS, LLC | 390,158 | $27M | -4,446 | 2026-06-30 | Filing |